Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss

Minerva Endocrinologica

Volumn 38, Issue 1, 2013, Pages 59-76

  Ravn, P ^a   Haugen, A G ^a   Glintborg, D ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Diet.; Overweight; Polycystic ovary syndrome; Weight loss

Indexed keywords

METFORMIN;

DRUG DOSE INCREASE; EMBASE; EXERCISE; HUMAN; HYPERANDROGENISM; LIFESTYLE MODIFICATION; LOW CALORY DIET; MEDLINE; MENSTRUAL CYCLE; MONOTHERAPY; OBESITY; OVARY POLYCYSTIC DISEASE; REVIEW; SYSTEMATIC REVIEW; WEIGHT REDUCTION;

BODY MASS INDEX; CALORIC RESTRICTION; EVIDENCE-BASED MEDICINE; EXERCISE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; OVERWEIGHT; POLYCYSTIC OVARY SYNDROME; WEIGHT LOSS;

EID: 84876589893     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;6:2745-9.
2. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;1:19-25.
3. Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. POSITION STATEMENT: Glucose Intolerance in Polycystic Ovary Syndrome A Position Statement of the Androgen Excess Society. J Clin Endocrinol Metab 2007;12:4546-56.
4. Glintborg D, Henriksen JE, Andersen M, Hagen C, Hangaard J, Rasmussen PE et al. Prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian premenopausal women with hirsutism as the referral diagnosis. Fertil Steril 2004;6:1570-9.
5. Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2011;3:1073-9.
6. Glintborg D, Mumm H, Hougaard DM, Ravn P, Andersen M. Smoking is associated with increased adrenal responsiveness, decreased prolactin levels and a more adverse lipid profile in 650 white patients with polycystic ovary syndrome. Gynecol Endocrinol 2011 [Epub ahead of print].
7. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001;10:1410-5.
8. Talbott EO, Zborowskii JV, Boudraux MY. Do women with polycystic ovary syndrome have an increased risk of cardiovascular disease? Review of the evidence. Minerva Ginecol 2004;1:27-39.
9. Pasquali R, Casimirri F, Venturoli S, Antonio M, Morselli L, Reho S et al. Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome. Metabolism 1994;6:706-13.
10. Lord J, Wilkin T Polycystic ovary syndrome and fat distribution: the central issue? Hum Fertil (Camb) 2002;2:67-71.
11. Ben Shlomo I. The polycystic ovary syndrome: what does insulin resistance have to do with it? Reprod Biomed Online 2003;1:36-42.
12. Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 2001;6:1255-60.
13. Horejsi R, Moller R, Rackl S, Giuliani A, Freytag U, Crailsheim K et al. Android subcutaneous adipose tissue topography in lean and obese women suffering from PCOS: comparison with type 2 diabetic women. Am J Phys Anthropol 2004;3:275-81.
14. Jovanovic VP, Carmina E, Lobo RA. Not all women diagnosed with PCOS share the same cardiovascular risk profiles. Fertil Steril 2010;3:826-32.
15. Bjorntorp P. The android woman - a risky condition. J Intern Med 1996;2:105-10.
16. Glintborg D, Andersen M. An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecol Endocrinol 2010;4:281-96.
17. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985;5:946-51.
18. Barr S, Hart K, Reeves S, Jeanes Y. Dietary intake, body composition and physical activity levels in women with polycystic ovary syndrome compared with healthy controls. J Hum Nutr Diet 2008;4:377.
19. Douglas CC, Norris LE, Oster RA, Darnell BE, Azziz R, Gower BA. Difference in dietary intake between women with polycystic ovary syndrome and healthy controls. Fertil Steril 2006;2:411-7.
20. Wright CE, Zborowski JV, Talbott EO, Hugh-Pemu K, Youk A. Dietary intake, physical activity, and obesity in women with polycystic ovary syndrome. Int J Obes Relat Metab Disord 2004;8:1026-32.
21. Alvarez-Blasco F, Luque-Ramirez M, Escobar-Morreale HF. Diet composition and physical activity in overweight and obese premenopausal women with or without polycystic ovary syndrome. Gynecol Endocrinol 2011;12:978-81.
22. Robinson S, Chan SP, Spacey S, Anyaoku V, Johnston DG, Franks S. Postprandial thermogenesis is reduced in polycystic ovary syndrome and is associated with increased insulin resistance. Clin Endocrinol (Oxf) 1992;6:537-43.
23. Cosar E, Koken G, Sahin FK, Akgun L, Ucok K, Genc A, Yilmazer M. Resting metabolic rate and exercise capacity in women with polycystic ovary syndrome. Int J Gynaecol Obstet 2008;1:31-4.
24. Glintborg D, Hermann AP, Andersen M, Hagen C, Beck-Nielsen H, Veldhuis JD et al. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertil Steril 2006;2:385-97.
25. Hirschberg AL, Naessen S, Stridsberg M, Bystrom B, Holtet J. Impaired cholecystokinin secretion and disturbed appetite regulation in women with polycystic ovary syndrome. Gynecol Endocrinol 2004;2:79-87.
26. Moran LJ, Noakes M, Clifton PM, Wittert GA, Tomlinson L, Galletly C et al. Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition. J Clin Endocrinol Metab 2004;7:3337-44.
27. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;8:2767-74.
28. Moran LJ, Noakes M, Clifton PM, Wittert GA, Le Roux CW, Ghatei MA et al. Postprandial ghrelin, cholecystokinin, peptide YY, and appetite before and after weight loss in overweight women with and without polycystic ovary syndrome. Am J Clin Nutr 2007;6:1603-10.
29. Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 2003;9:1928-32.
30. Stamets K, Taylor DS, Kunselman A, Demers LM, Pelkman CL, Legro RS. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril 2004;3:630-7.
31. Colquitt JL, Picot J, Loveman E, Clegg AJ. Surgery for obesity. Cochrane Database Syst Rev 2009;2:CDO03641.
32. Mitri J, Hamdy O. Diabetes medications and body weight. Expert Opin Drug Saf 2009;5:573-84.
33. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004;3:CD004094.
34. Pirozzo S, Summerbell C, Cameron C, Glasziou P. Advice on low-fat diets for obesity. Cochrane Database Syst Rev 2002;2:CD003640.
35. Quigley S, Colledge J, Mukherjee S, Patel K. Bariatric surgery: a review of normal postoperative anatomy and complications. Clin Radiol 2011;10:903-14.
36. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;7631:1194-9.
37. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;2:812-9.
38. Marsh KA, Steinbeck KS, Atkinson FS, Petocz P, Brand-Miller JC. Effect of a low glycemic index compared with a conventional healthy diet on polycystic ovary syndrome. Am J Clin Nutr 2010;1:83-92.
39. Egan N, Read A, Riley P, Atiomo W. Evaluating compliance to a low glycaemic index (GI) diet in women with polycystic ovary syndrome (PCOS). BMC Res Notes 2011;53.
40. Ornstein RM, Copperman NM, Jacobson MS. Effect of weight loss on menstrual function in adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2011;3:161-5.
41. Bruner B, Chad K, Chizen D. Effects of exercise and nutritional counseling in women with polycystic ovary syndrome. Appl Physiol Nutr Metab 2006;4:384-91.
42. Galletly C, Moran L, Noakes M, Clifton P, Tomlinson L, Norman R. Psychological benefits of a high-protein, low-carbohydrate diet in obese women with polycystic ovary syndrome - a pilot study. Appetite 2007;3:590-3.
43. Thomson RL, Buckley JD, Noakes M, Clifton PM, Norman RJ, Brinkworth GD. The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008;9:3373-80.
44. Palomba S, Giallauria F, Falbo A, Russo T, Oppedisano R, Tolino A et al. Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. Hum Reprod 2008;3:642-50.
45. Thomson RL, Buckley JD, Lim SS, Noakes M, Clifton PM, Norman RJ et al. Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome. Fertil Steril 2010;5:1812-6.
46. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003;7:908-15.
47. Goldenberg N, Glueck CJ, Loftspring M, Sherman A, Wang P. Metformin-diet benefits in women with polycystic ovary syndrome in the bottom and top quintiles for insulin resistance. Metabolism 2005;1:113-21.
48. Qublan HS, Yannakoula EK, Al-Qudah MA, El-Uri FI. Dietary intervention versus metformin to improve the reproductive outcome in women with polycystic ovary syndrome. A prospective comparative study. Saudi Med J 2007;11:1694-9.
49. Gambineri A, Patton L, Vaccina A, Cacciari M, Morselli-Labate AM, Cavazza C et al. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab 2006;10:3970-80.
50. Moran LJ, Noakes M, Clifton PM, Wittert GA, Williams G, Norman RJ. Short-term meal replacements followed by dietary macronutrient restriction enhance weight loss in polycystic ovary syndrome. Am J Clin Nutr 2006;1:77-87.
51. Tolino A, Gambardella V, Caccavale C, D'Ettore A, Giannotti F, D'Anto V et al. Evaluation of ovarian functionality after a dietary treatment in obese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2005;1:87-93.
52. Harrison CL, Stepto NK, Hutchison SK, Teede HJ. The impact of intensified exercise training on insulin resistance and fitness in overweight and obese women with and without polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012;3:351-7.
53. Giallauria F, Palomba S, Maresca L, Vuolo L, Tafuri D, Lombardi G et al. Exercise training improves autonomic function and inflammatory pattern in women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2008;5:792-8.
54. Vigorito C, Giallauria F, Palomba S, Cascella T, Manguso F, Lucci R et al. Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;4:1379-84.
55. Jedel E, Labrie F, Oden A, Holm G, Nilsson L, Janson PO et al. Impact of electro-acupuncture and physical exercise on hyperandrogenism and oligo/amenorrhea in women with polycystic ovary syndrome: a randomized controlled trial. Am J Physiol Endocrinol Metab 2011;1:E37-E45.
56. Redman LM, Elkind-Hirsch K, Ravussin E. Aerobic exercise in women with polycystic ovary syndrome improves ovarian morphology independent of changes in body composition. Fertil Steril 2011;8:2696-9.
57. Otta CF, Wior M, Iraci GS, Kaplan R, Torres D, Gaido MI et al. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial. Gynecol Endocrinol 2010;3:173-8.
58. Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 2006;1:80-9.
59. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 2008;11:4299-306.
60. Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004;2:421-9.
61. Karimzadeh MA, Javedani M. An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome. Fertil Steril 2010;1:216-20.
62. Ladson G, Dodson WC, Sweet SD, Archibong AE, Kunselman AR, Demers LM et al. The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. Fertil Steril 2011;3:1059-66.
63. Pelletier L, Baillargeon JP. Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice. Fertil Steril 2010;7:2665-9.
64. Allen HF, Mazzoni C, Heptulla RA, Murray MA, Miller N, Koenigs L et al. Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab 2005;8:761-8.
65. Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002;2:569-74.
66. Hahn S, Benson S, Elsenbruch S, Pleger K, Tan S, Mann K et al. Metformin treatment of polycystic ovary syndrome improves health-related quality-of-life, emotional distress and sexuality. Hum Reprod 2006;7:1925-34.
67. Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 2005;8:4593-8.
68. Qublan HS, Al-Khaderei S, Abu-Salem AN, Al-Zpoon A, Al-Khateeb M, Al-Ibrahim N et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. J Obstet Gynaecol 2009;7:651-5.
69. Sathyapalan T, Cho LW, Kilpatrick ES, Coady AM, Atkin SL. Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2009;1:124-8.
70. Ghandi S, Aflatoonian A, Tabibnejad N, Moghaddam MH. The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study. J Assist Reprod Genet 2011;7:591-6.
71. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002;4:1555-9.
72. Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J Clin Endocrinol Metab 2005;2:729-33.
73. Glueck CJ, Aregawi D, Winiarska M, Agloria M, Luo G, Sieve L et al. Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab 2006;6:831-42.
74. Glueck CJ, Aregawi D, Agloria M, Winiarska M, Sieve L, Wang P. Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome. Metabolism 2006;12:1582-9.
75. Gambineri A, Pelusi C, Genghini S, Morselli-Labate AM, Cacciari M, Pagotto U et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004;2:241-9.
76. Vanky E, Salvesen KA, Carlsen SM. Six-month treatment with low-dose dexamethasone further reduces androgen levels in PCOS women treated with diet and lifestyle advice, and metformin. Hum Reprod 2004;3:529-33.
77. Moran LJ, Noakes M, Clifton PM, Wittert GA, Williams G, Norman RJ. Short-term meal replacements followed by dietary macronutrient restriction enhance weight loss in polycystic ovary syndrome. Am J Clin Nutr 2006;1:77-87.
78. Andersen P, Seljeflot I, Abdelnoor M, Arnesen H, Dale PO, Lovik A, Birkeland K. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 1995;5:611-6.
79. Moran LJ, Noakes M, Clifton PM, Norman RJ. The effect of modifying dietary protein and carbohydrate in weight loss on arterial compliance and postprandial lipidemia in overweight women with polycystic ovary syndrome. Fertil Steril 2010;6:2451-4.
80. Foster-Powell K, Holt SH, Brand-Miller JC. International table of glycemic index and glycemic load values: 2002. Am J Clin Nutr 2002;1:5-56.
81. Latner JD, Schwartz M. The effects of a high-carbohydrate, high-protein or balanced lunch upon later food intake and hunger ratings. Appetite 1999;1:119-28.
82. Pasquali R, Gambineri A, Cavazza C, Ibarra GD, Ciampaglia W, Cognigni GE, Pagotto U. Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. Eur J Endocrinol 2011;1:53-60.
83. Humphreys L, Costarelli V. Implementation of dietary and general lifestyle advice among women with polycystic ovarian syndrome. J R Soc Promot Health 2008;4:190-5.
84. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999;4:1470-4.
85. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007;2:405-13.